Taysha Gene Therapies, Inc. (TSHA) financial statements and ratios from SEC XBRL: revenue $9.77M (TTM), net margin -1115.3%, revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $9.77M |
| Net Margin | -1115.3% |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | 44.4% |
| FCF Growth (YoY) | 100.3% |
| Price / Book | 4.53 |
| Price / Sales | 319.58 |
| FCF Yield | -7.6% |
| Altman Z-Score | 8.02 (safe) |
| Sector P/E (Healthcare) | 21.6 |
TSHA overview · TSHA earnings · TSHA KPIs · TSHA investor relations · TSHA ownership · TSHA peers · TSHA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.